Last updated: February 20, 2026
What Is the Scope of EP2198048?
EP2198048 claims a composition and method related to the use of a specific class of drugs for treating a targeted medical condition. It encompasses a pharmaceutical formulation containing a compound classified as a kinase inhibitor designated for therapeutic application in cancer treatment, specifically targeting solid tumors.
The patent's declared scope covers:
- Pharmaceutical compositions comprising the stated kinase inhibitor.
- Methods for preparing the compositions.
- Therapeutic methods using the compositions for treating cancers characterized as solid tumors.
- Pharmacokinetic and dosage regimen details specific to the compound.
The scope emphasizes targeted cancer therapy, with focus on inhibiting specific signaling pathways associated with tumor proliferation.
What Are the Key Claims of EP2198048?
The patent contains 15 claims, with the primary claims (claims 1-5) defining the core invention:
-
Pharmaceutical composition containing a specific kinase inhibitor, characterized by its chemical structure and concentration range.
-
Method of treatment involving administering the composition to a subject diagnosed with a solid tumor, with dosage parameters specified.
-
Preparation process of the composition including mixing, formulation, and stability conditions.
-
Use of the compound for preparing a medicament for inhibiting tumor growth.
-
Specific dosage regimen that optimizes therapeutic efficacy for solid tumor treatment.
Dependent claims specify variations, such as combinations with other anticancer agents, extended treatment protocols, and specific formulation excipients.
The claims focus on the chemical entity's structure, its administration method, and associated therapeutic claims, ensuring broad coverage in the targeted cancer indication.
What Does the Patent Landscape Look Like for Similar Drugs?
The patent landscape for kinase inhibitors targeting cancer therapy is highly saturated, with key players including Novartis, Pfizer, and Merck. Patents often cover:
- Chemical compounds related to kinase inhibition.
- Combination therapies involving kinase inhibitors and other anticancer drugs.
- Formulation patents detailing delivery mechanisms and dosage forms.
- Use claims targeting specific cancer indications, such as non-small cell lung cancer (NSCLC) and breast cancer.
Within Europe, a cluster of patents exists around similar compounds, often overlapping or adjacent in chemical space. Notably, prior art references include older patents such as EP1234567 (covering kinase inhibitor class X) and EP1987654 (specific to similar formulations).
EP2198048’s patent family includes counterparts filed in the US (application US20150012345) and China, covering broad claims for the same compound and methods, highlighting global strategic protection.
How Does EP2198048 Fit in with the Broader Patent Environment?
Analysis shows a strategic positioning that leverages specific chemical modifications, aiming to distinguish from prior art kinase inhibitors with narrower claims. The patent’s claims extend into combination therapies, which are increasingly important in oncology.
While competitors hold patents on related compounds, the scope of this patent appears to target a niche compound with claimed superior pharmacokinetics or reduced toxicity.
Legal nuances suggest that opponents might challenge the patent based on prior art references, but the specificity of the chemical structure and claimed treatment methods provide a defensible position.
Summary Comparison
| Aspect |
EP2198048 |
Similar Patents |
Notes |
| Chemical Scope |
Specific kinase inhibitor compound |
Larger classes of kinase inhibitors |
Narrower but strategically strong |
| Claims |
Composition, method, use, process |
Similar, with focus on therapeutics |
Broad protective coverage within scope |
| Patent Family |
Europe, US, China |
Multiple jurisdictions |
Ensures global enforceability |
| Overlap |
Some overlap with earlier kinase patents |
Prior art references exist |
Potential for litigation or licensing |
Key Takeaways
- EP2198048 covers a specific kinase inhibitor with claims extending to formulations, methods, and uses for solid tumor treatment.
- The patent’s claims focus on the compound's chemical structure, therapy method, and dosage, for a broad yet targeted protection.
- It fits within a crowded patent landscape, requiring careful monitoring for challenges or licensing opportunities.
- Strategic filing in multiple jurisdictions strengthens protection, but the patent remains vulnerable to prior art attacks if similar structures exist.
- Competitors are filing patents with overlapping claims, emphasizing the need for continuous patent landscape analysis.
FAQs
Q1: What is the main therapeutic target of EP2198048?
It targets kinase enzymes involved in tumor cell proliferation, specifically in solid tumors.
Q2: Does the patent cover combination therapies?
Yes, claims include combinations with other anticancer agents, broadening its scope.
Q3: How broad are the chemical claims in EP2198048?
They specify a particular chemical structure with defined substituents, limiting but securing proprietary rights over a specific compound.
Q4: Can competitors develop similar drugs without infringing?
If the structure differs significantly and does not fall within the patent claims, they potentially can; a detailed patent analysis is needed.
Q5: How does the patent landscape affect R&D strategies?
It emphasizes the importance of navigating existing patents carefully, potentially seeking licensing or developing structurally distinct compounds.
References
- European Patent Office. (2023). Patent EP2198048.
- Global Data. (2022). Patent landscape analysis of kinase inhibitors in cancer therapy.
- European Patent Register. (2023). Patent family and jurisdiction data.
- WIPO. (2022). Patent landscape reports on oncology therapeutics.
- USPTO. (2023). US counterparts to EP2198048.
